Disclosed are methods of, and assay and kits for, detecting and diagnosing methods of detecting, diagnosing, vulnerable carotid artery disease capable of becoming acutely symptomatic using the levels of Resolvin D1 (RvD1), docosahexaenoic acid (DHA), and arachidonic acid (AA). Also disclosed are methods of treating carotid artery disease and methods of identifying agents for use in the treatment of carotid artery disease.

A method is disclosed comprising obtaining or acquiring image or other data from one or more regions of a target using an imaging sensor. The image or other data may then be used to determine one or more regions of interest of the target. An ambient ionisation ion source may then be used to generate aerosol, smoke or vapour from one or more regions of the target.

An apparatus for mass spectrometry and/or ion mobility spectrometry is disclosed comprising a first device arranged and adapted to generate aerosol, smoke or vapour from a target and one or more second devices arranged and adapted to aspirate aerosol, smoke, vapour and/or liquid to or towards an analyser. A liquid trap or separator is provided to capture and/or discard liquid aspirated by the one or more second devices.

Disclosed is a method for detecting the presence, progression or risk of onset of neurodegenerative disease, based on determination of the concentration of lipid markers in an individuals serum or plasma sample.

The present invention relates to methods for the diagnosis or prognosis of conditions caused by defects in cholesterol bio synthesis, such as Smith-Lemli-Opitz syndrome (SLOS), in particular to early diagnostic methods including in utero methods. In one aspect, the method comprises detecting in a biological sample levels of delta-5 bile acid conjugated with 2-(acetylamino)-2-deoxy-D-glucose (GlcNAc) of formula (I)

##STR00001##

An apparatus for mass spectrometry and/or ion mobility spectrometry is disclosed comprising a first device arranged and adapted to generate aerosol, smoke or vapor from a target and one or more second devices arranged and adapted to aspirate aerosol, smoke, vapor and/or liquid to or towards an analyzer. A liquid trap or separator is provided to capture and/or discard liquid aspirated by the one or more second devices.

The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system.

A method of spectrometric analysis comprises obtaining one or more sample spectra for an aerosol, smoke or vapour sample. The one or more sample spectra are subjected to pre-processing and then multivariate and/or library based analysis so as to classify the aerosol, smoke or vapour sample. The results of the analysis are used for various surgical or non-surgical applications.

The present disclosure relates to a kit and method for testing harmful heavy metals onsite, which can determine the presence or absence of harmful heavy metals and the degree of contamination with harmful heavy metals dissolved in water or contained in sediment, soil, deep-sea mining tailings and the like. The kit includes a receiving member and a diagnostic solution containing a biosurfactant, which is accommodated in the receiving member and undergoes an ion exchange reaction with a liquid including harmful heavy metals or a solid sample from which harmful heavy metals are leached in a liquid phase.

The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.